| Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16, 1-15, 2018 | 715 | 2018 |
| Transplantation of discarded livers following viability testing with normothermic machine perfusion H Mergental, RW Laing, AJ Kirkham, MTPR Perera, YL Boteon, J Attard, ... Nature communications 11 (1), 2939, 2020 | 384 | 2020 |
| Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial C Craddock, N Jilani, S Siddique, C Yap, J Khan, S Nagra, J Ward, ... Biology of Blood and Marrow Transplantation 22 (2), 385-390, 2016 | 203 | 2016 |
| Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose–volume relationships and role for inverse planning LM Tho, M Glegg, J Paterson, C Yap, A MacLeod, M McCabe, ... International Journal of Radiation Oncology* Biology* Physics 66 (2), 505-513, 2006 | 186 | 2006 |
| Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide CN Harrison, AJ Mead, A Panchal, S Fox, C Yap, E Gbandi, A Houlton, ... Blood, The Journal of the American Society of Hematology 130 (17), 1889-1897, 2017 | 169 | 2017 |
| Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial PN Newsome, R Fox, AL King, D Barton, NN Than, J Moore, C Corbett, ... The Lancet Gastroenterology & Hepatology 3 (1), 25-36, 2018 | 166 | 2018 |
| The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design M Dimairo, P Pallmann, J Wason, S Todd, T Jaki, SA Julious, AP Mander, ... bmj 369, 2020 | 146 | 2020 |
| Development of clinical criteria for functional assessment to predict primary nonfunction of high‐risk livers using normothermic machine perfusion H Mergental, BTF Stephenson, RW Laing, AJ Kirkham, DAH Neil, ... Liver Transplantation 24 (10), 1453-1469, 2018 | 132 | 2018 |
| Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single … RW Laing, H Mergental, C Yap, A Kirkham, M Whilku, D Barton, ... BMJ open 7 (11), e017733, 2017 | 128 | 2017 |
| How to design a dose-finding study using the continual reassessment method GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ... BMC medical research methodology 19, 1-15, 2019 | 104 | 2019 |
| A comparison of short-term and long-term air pollution exposure associations with mortality in two cohorts in Scotland IJ Beverland, GR Cohen, MR Heal, M Carder, C Yap, C Robertson, ... Environmental health perspectives 120 (9), 1280-1285, 2012 | 102 | 2012 |
| Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial CN Harrison, J Nangalia, R Boucher, A Jackson, C Yap, J O'Sullivan, ... Journal of Clinical Oncology 41 (19), 3534-3544, 2023 | 96 | 2023 |
| When to keep it simple–adaptive designs are not always useful JMS Wason, P Brocklehurst, C Yap BMC medicine 17, 1-7, 2019 | 80 | 2019 |
| Embracing model-based designs for dose-finding trials SB Love, S Brown, CJ Weir, C Harbron, C Yap, B Gaschler-Markefski, ... British journal of cancer 117 (3), 332-339, 2017 | 80 | 2017 |
| Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia C Craddock, D Slade, C De Santo, R Wheat, P Ferguson, A Hodgkinson, ... Journal of Clinical Oncology 37 (7), 580-588, 2019 | 72 | 2019 |
| Oncology phase I trial design and conduct: time for a change-MDICT Guidelines 2022 D Araujo, A Greystoke, S Bates, A Bayle, E Calvo, L Castelo-Branco, ... Annals of Oncology 34 (1), 48-60, 2023 | 63 | 2023 |
| Implementation of platform trials in the COVID-19 pandemic: a rapid review AM Vanderbeek, JM Bliss, Z Yin, C Yap Contemporary Clinical Trials 112, 106625, 2022 | 58 | 2022 |
| Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive … BA Fisher, T Veenith, D Slade, C Gaskell, M Rowland, T Whitehouse, ... The Lancet Respiratory Medicine 10 (3), 255-266, 2022 | 51 | 2022 |
| Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance C Guo, A Sharp, B Gurel, M Crespo, I Figueiredo, S Jain, U Vogl, ... Nature 623 (7989), 1053-1061, 2023 | 50 | 2023 |
| Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial AG Pratt, S Siebert, M Cole, DD Stocken, C Yap, S Kelly, M Shaikh, ... The Lancet Rheumatology 3 (5), e337-e346, 2021 | 48 | 2021 |
